US brand comparison

Wegovy vs Zepbound

In SURMOUNT-5, a head-to-head trial of the injections, mean weight change was −13.7% on semaglutide (Wegovy) and −20.2% on tirzepatide (Zepbound) over 72 weeks. Wegovy contains semaglutide; Zepbound contains tirzepatide.

Compare prices Change comparison

Wegovy vs Zepbound: active ingredients, formulations, and manufacturers
Compare	Wegovy	Zepbound
Active ingredient	SemaglutideGLP-1	TirzepatideGIP/GLP-1
How it is taken	Injection Once weekly Tablet Once daily, on an empty stomach	Injection Once weekly
Manufacturer	Novo Nordisk	Eli Lilly

Direct evidence

What was actually compared

SURMOUNT-5

Peer-reviewed paper

Wegovy injection vs Zepbound

Adults with obesity, or overweight with a weight-related condition, without diabetes.

751 participants · 72 weeks · Randomized, open-label

Mean weight change (% of body weight)

Treatment-regimen analysis, regardless of treatment adherence.

SURMOUNT-5: Mean weight change at 72 weeks. Treatment-regimen analysis, regardless of treatment adherence.
Treatment & dose	Change
Semaglutide (Wegovy)1.7 or 2.4 mg weekly injection	−13.7%
Tirzepatide (Zepbound)10 or 15 mg weekly injection	−20.2%

Tirzepatide produced greater mean weight reduction in this trial. Both groups used their maximum tolerated dose.

This trial did not test Wegovy tablets or Wegovy HD. It was not powered to establish a safety or tolerability advantage. Study averages do not predict an individual's result.

Read the paper PubMed abstract Sponsor's analysis detailsReviewed Sep 28, 2026

Weight-loss results by formulation

Each result belongs to its named trial and dose. Separate trials have different participants and methods; these figures are not a direct comparison.

Wegovy vs Zepbound: sourced weight-loss results by formulation
Compare	Wegovy	Zepbound
Injection evidence	−14.9% (-14.9% at 68 wks · STEP 1 · 2.4 mg weekly (Wegovy)) STEP 1 · -14.9% at 68 wks 2.4 mg weekly (Wegovy) Accounts for treatment discontinuation	−20.9% (-20.9% at 72 wks · SURMOUNT-1 · 15 mg weekly (Zepbound)) SURMOUNT-1 · -20.9% at 72 wks 15 mg weekly (Zepbound) Accounts for treatment discontinuation
Tablet evidence	−13.6% (-13.6% at 64 wks · OASIS 4 · 25 mg daily (Wegovy tablet)) OASIS 4 · -13.6% at 64 wks 25 mg daily (Wegovy tablet) Accounts for treatment discontinuation	No reviewed weight-loss result for this brand and formulation.

Product-specific costs

Entry price and maintenance price

Self-pay quotes, not insurance estimates. Each figure identifies the product, provider, and dose where published.

Wegovy vs Zepbound: published self-pay prices by formulation
Compare	Wegovy	Zepbound
Injection prices	Advertised entry price $199/fill initially 28-day supply ≈ $213.21 per 30 days at this quoted rate Offer through Dec 31, 2026 Checked Oct 20, 2026 Wegovy pen (standard doses 0.25-2.4 mg) NovoCare (Novo Nordisk) · Manufacturer direct first two 28-day fills at 0.25 or 0.5 mg for new patients whose prescription is written and received by Dec 31, 2026 Price conditions first two 28-day fills at 0.25 or 0.5 mg for new patients whose prescription is written and received by Dec 31, 2026 After the introductory offer, standard doses cost $349 per box of four pens, a 28-day supply. Wegovy HD (7.2 mg) is $399. Introductory fills must ship by Jan 31, 2027. Eligibility and restrictions apply. 28-day supply View offer Published maintenance dose $349/28 days 28-day supply ≈ $373.93 per 30 days at this quoted rate Checked Oct 20, 2026 At 2.4 mg Wegovy pen (standard doses 0.25-2.4 mg) NovoCare (Novo Nordisk) · Manufacturer direct Published price at 2.4 mg Price conditions Published price at 2.4 mg After the introductory offer, standard doses cost $349 per box of four pens, a 28-day supply. Wegovy HD (7.2 mg) is $399. Introductory fills must ship by Jan 31, 2027. Eligibility and restrictions apply. One price for every standard dose (0.25-2.4 mg). 28-day supply View offer	Advertised entry price $299-$449/28 days 28-day supply ≈ $320.36 per 30 days at this quoted rate Checked Oct 20, 2026 Zepbound KwikPen (multi-dose pen) LillyDirect (Eli Lilly) · Manufacturer direct self-pay cash, by dose ($299 / $399 / $449) Price conditions self-pay cash, by dose ($299 / $399 / $449) Each pen holds four doses, one month's (28-day) supply. $299 at 2.5 mg and $399 at 5 mg; $449 at 7.5 to 15 mg under the Self Pay Journey offer, which holds only with a refill within 45 days. 28-day supply View offer Published maintenance dose $449/28 days 28-day supply ≈ $481.07 per 30 days at this quoted rate Checked Oct 20, 2026 At 15 mg Zepbound KwikPen (multi-dose pen) LillyDirect (Eli Lilly) · Manufacturer direct Published price at 15 mg Price conditions Published price at 15 mg Each pen holds four doses, one month's (28-day) supply. $299 at 2.5 mg and $399 at 5 mg; $449 at 7.5 to 15 mg under the Self Pay Journey offer, which holds only with a refill within 45 days. Self Pay Journey price for 7.5-15 mg with a refill within 45 days; otherwise $499 (7.5 mg) or $699 (10-15 mg). 28-day supply View offer
Tablet prices	Advertised entry price from $149/mo 30-day supply $149 per 30 days at this quoted rate Checked Oct 20, 2026 Wegovy pill (oral semaglutide) NovoCare (Novo Nordisk) · Manufacturer direct self-pay cash, lowest dose (1.5 mg) Price conditions self-pay cash, lowest dose (1.5 mg) $149/mo for 1.5 mg; $199 for 4 mg; $299 for 9 mg and 25 mg. 30-day supply View offer Published maintenance dose $299/mo 30-day supply $299 per 30 days at this quoted rate Checked Oct 20, 2026 At 25 mg Wegovy pill (oral semaglutide) NovoCare (Novo Nordisk) · Manufacturer direct Published price at 25 mg Price conditions Published price at 25 mg $149/mo for 1.5 mg; $199 for 4 mg; $299 for 9 mg and 25 mg. $149 (1.5 mg), $199 (4 mg), $299 (9 mg and 25 mg). 30-day supply View offer	No reviewed tablet formulation in this brand record.

All 18 Wegovy offers All 16 Zepbound offers

How these quotes are selected

For each price basis, we prefer a recently checked manufacturer-direct quote, then a recently checked provider quote for that brand and formulation. Within each group, documented 30-day costs come first, lowest to highest. Quotes without a documented supply period have no cost rank. Older quotes appear as dated references only when no current quote is tracked. Providers may differ between entry and maintenance prices. Missing maintenance prices are never replaced with entry prices. Compounded products, combined brand quotes, and membership-only fees are excluded. Prices at different doses are not equivalent treatment costs; confirm supply length, eligibility, and added fees.

Every cash quote was checked on or after Oct 15, 2026. Each quote shows its own check date. A quoted maintenance dose is not a dosing recommendation. Our methodology

US prescribing information

Approved uses by formulation

Eligibility, contraindications, and warnings are in each product's full prescribing information.

Wegovy vs Zepbound: reviewed approved uses by formulation
Compare	Wegovy	Zepbound
Injection	Weight management in eligible adults and adolescents 12+ with obesity; cardiovascular risk reduction in eligible adults; noncirrhotic MASH with moderate to advanced liver fibrosis in adults (accelerated approval). US prescribing information (Wegovy Injection prescribing information) Reviewed Sep 6, 2026	Weight management in adults with obesity, or overweight with a weight-related condition; moderate to severe obstructive sleep apnea in adults with obesity. US prescribing information (Zepbound Injection prescribing information) Reviewed Sep 6, 2026
Tablet	Weight management and cardiovascular risk reduction in eligible adults. The tablet is not labeled for MASH or pediatric use. US prescribing information (Wegovy Tablet prescribing information) Reviewed Sep 6, 2026	No reviewed tablet label in this brand record. Ingredient record

Full evidence and safety information

Semaglutide: evidence & safety Tirzepatide: evidence & safety

Compare the active ingredients

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.